Replies to post #155600 on Biotech Values

[wdr7]

Why do they enroll KRAS wild type patients?

[BTH]

Did you know this is being presented this week at ASCO GI?

Second-line therapy of KRAS-mutated mCRC with the MEK inhibitor selumetinib in combination with irinotecan: An AGICC study (Hochster, et al, abstract 380)